Abstract

**Background:** Onychomycosis is a common infection of the nail bed that can negatively affect patient quality of life. The complete cure rate for systemic drugs is 23-37% while the complete cure rate for topical drug therapy with efinaconazole is 27.7%. Laser Pharmacology™ presents a promising alternative using a dual-diode laser employing wavelengths of 635 nm and 405 nm to create a drug-like response in living tissue (Erchonia® Lunula Laser®, Erchonia Corporation, Melbourne, FL). The purpose of this clinical study is to assess the safety and efficacy of mycological and complete cure rates of the dual diode nonthermal laser.

**Methods:** Enrolled subjects (N=20) had onychomycosis affecting the great toenail, confirmed by a positive mycological culture. Subjects were predominantly female (70%) with a mean (SD) age of 59.9 (9.0) years. Affected toenails were treated with 12-minute laser light sessions, each week for 4 weeks, then one session at 3, 5, 7, 9 and 11 months. Study assessments were completed at 3, 5, 7, 9, 11, 12 and 14 months.

**Results:** Most subjects achieved a Clinical Cure (n=14, 70%) and Mycological Cure (n=19, 95%) of the affected great toenail. At 12 months, most subjects also achieved Clinical Efficacy (n=18, 90%), Mycological Cure (n=19, 95%) and unaffected New Nail Growth (n=20, 100%).

**Conclusion:** This study confirms the safety and effectiveness of a non-thermal 635 nm/405 nm dual-diode laser device for providing mycological and complete cure rate in onychomycosis-affected toenails following four weekly and five bi-monthly treatment sessions.

**Trial registration:** ClinicalTrials.gov Identifier NCT03066336, registered 02/28/2017, https://clinicaltrials.gov/ct2/show/NCT03066336
on different chemical, mechanical and physical methods to improve drug delivery [7]. Efinaconazole and tavaborole have shown some improvement in the transungual drug delivery as they do not bind to the keratin present in the nails [8]. This is the result of the development of Polypseudorotaxanes based nail lacquer with the incorporation of penetration enhancer which is able to achieve a high rate of drug penetration and retention [9]. The complete cure rate for FDA approved topical drug therapy efinaconazole is 15.2-17.8% [10]. Several thermal lasers are available for treating onychomycosis but only cleared to temporarily increase the amount of clear nail, and lack published data showing mycological or complete cure. Disadvantages of thermal lasers include mild treatment-related burning or pain and should be used with caution with patients that are insensitive, such as patients with diabetes and peripheral vascular dysfunction. Additionally, thermal lasers cannot provide total coverage to the nail plate, subcutaneous tissues, and the germinal layer. This is crucial as the matrix extends approximately 5 mm beneath the proximal nail fold.

Laser Pharmacology™ is a series of nonthermal interactions caused by laser photons that produce a change in physiology through similar, if not the same, biological pathways of pharmaceuticals. This principle has previously demonstrated effectiveness for several conditions including reducing low back pain [11], neck and shoulder pain [12], plantar fasciitis [13], musculoskeletal pain, post-surgical pain [14], and non-invasive body contouring [15]. All of which have been granted an FDA 510(k) clearance for their respective indications.

The primarily attribute for laser to produce antifungal activity is the laser wavelength. A novel laser device uses a dual-wavelength design incorporating 635nm (red) and 405nm (violet) (Erchonia® Lunula Laser®; Erchonia Corporation. Melbourne, FL). Violet light is primarily absorbed by flavoproteins [16] which mediates a wide array of biological processes such as bioluminescence, quenching of oxidative stress-induced radicals, DNA repair, and apoptosis [17] Red light is absorbed by cytochrome C oxidase which increases mitochondrial enzyme activity and subsequent ATP production [18]. Photo-acceptor molecules are similar to drug receptors. Following administration, the drug typically binds to a specific receptor on the cell wall and influences intracellular activity. Laser Pharmacology™ targets specific photoreceptor(s) within cells that are capable of influencing a diverse downstream cascade to produce a similar “drug-like effect.”

With respect to treating onychomycosis, the 635nm (red) diode has been shown to activate IL10 and P13 kinase/eNOS signaling pathways, producing the powerful vasodilator Nitric Oxide (NO). Nitric oxide promotes endothelial cell migration and neovascularization [19]. The 405nm (violet) diode has demonstrated the ability to activate flavoproteins, thereby upregulating the production of Reactive Oxygen Species (ROS) leading to the generation of hydrogen peroxide, hypochlorous acid, and hydroxyl radicals [20]. Another potential photo-target for the 405 nm wavelength is nicotinamide adenine dinucleotide phosphate oxidase (NOX) which also generates ROS [21]. NOX transfers electrons from cytosolic NADPH to Flavin Adenine Dinucleotide (FAD) and extracellular molecular oxygen to generate superoxide. Stimulation of NOX provides two benefits: phagocytes activation and exposing susceptible dermatophytes to the toxic effects of ROS.

The Laser Pharmacology™ effect in relation to treating onychomycosis, is produced by the combination of the red and violet wavelengths. Peroxynitrite, a potent and proven antifungal agent is formed following the simultaneous exposure to ROS (violet light) and NO (red light). When targeting fungal colonies, increased peroxynitrite has powerful cytotoxic effects, reducing the number of fungal pathogens [22]. Peroxynitrite was found to be more potent than hydrogen peroxide in oxidizing thiols, and induced heat shock proteins (Hsp70) and enhanced the ubiquitination of proteins [23]. Peroxynitrite is a potent stressor in yeast, inducing oxidative damage and protein nitration. In a separate study, Weller et al. (2001) demonstrated the antimicrobial effects of peroxynitrite on dermatophytic fungi, yeast, and bacteria [24]. The authors concluded that peroxynitrite is a novel antimicrobial agent for the eradication of skin pathogens [24].

Non-thermal lasers must not be associated with thermal lasers as the mechanism of action is completely different. Thermal lasers rely on heat transfer to fungal mycelium, reaching fungicidal temperatures of 43°C to 51°C for 2-4 minutes, while lower temperatures can stimulate fungal growth [25].

A previous retrospective study demonstrated the safety and efficacy of the Lunula Laser device leading to FDA 510(k) market clearance for the temporary increase of clear nail in patients with onychomycosis caused by dermatophytes (e.g., Trichophyton rubrum and T. mentagrophytes) and/or yeasts (e.g., Candida albicans) (Erchonia Corporation. Melbourne, FL) [26]. The FDA market clearance was based on 100 retrospectively evaluated great toenails at baseline (pre-procedure administration) and 6 months post-procedure (study endpoint). The purpose of this clinical study is to further demonstrate the efficacy of mycological and complete cure rate of the Lunula nonthermal laser for the treatment of onychomycosis of the toenail.

Methods

Study subjects

The study was conducted in Mesa, Arizona at the Arizona Institute of Footcare Physicians. Mesa, has a hot desert type of climate, classified as BWh by the Köppen–Geiger system. In Mesa, the average annual temperature is 21.3 °C, with rainfall around 221 mm per year. All twenty (n=20) subjects were recruited from among the investigators’ pool of patients and individuals responding to local recruitment flyers. Subjects with onychomycosis of the great toenail completed a mycological evaluation at the study site to confirm a positive mycological culture for Trichophyton rubrum or other common
types of dermatophyte and clinical involvement of 20 to 50% of the target toenail. Subjects agreed to refrain from applying non-study treatments for their toenail onychomycosis and nail cosmetics such as clear or colored nail lacquers throughout the study.

**Study device**

The treatment device is a dual-diode laser (Erchonia® Lunula Laser®, Erchonia Corporation. Melbourne, FL) employing wavelengths of 635 nm and 405 nm which are classified by the Center for Devices and Radiological Health as Class II laser diodes. The device has been previously FDA-cleared for the temporary increase of clear nail in patients with onychomycosis.

**Procedure**

The affected toenails were treated with the laser for 12-minute sessions, weekly for 4 weeks, then one session at 3, 5, 7, 9, and 11 months. Study assessments were completed at 3, 5, 7, 9, 11, 12 and 14 months and included digital images, measurement of clear nail length, percent of onychomycosis involvement, and mycological evaluation. Mycological testing was completed using an enriched dermatophyte medium for detecting dermatophytes from clinical specimens (InTray™ DM; Biomed Diagnostics, Inc., White City, OR). Mycological testing was completed at the end of Week 4 and months 3, 5, 7, 9, 11, and 14.

**Outcome measures**

Individual Responders were subjects achieving Complete Cure at 12 months post-treatment having satisfied Clinical Cure and Mycological Cure criteria. Clinical Cure was defined as a ≥12 mm increase in clear nail with evidence of distal growth of the affected area at 12 months, or complete clearance after 12 months if <12 mm distal nail was involved prior to treatment. Mycologic Cure is defined as a negative culture for onychomycosis. Overall Study Success was defined as a ≥70% Clinical Cure rate and ≥80% Mycological Cure rate among those toenails at 12 months.

The 12-month secondary endpoints were Clinical Efficacy, defined as <10% of affected target nail area, Mycological Cure, and unaffected New Nail Growth, defined as the change in baseline healthy nail measurement.

**Statistical analysis**

As enrolled subjects completed all study visits and assessments, only the ITT analysis was performed for primary outcome study success evaluation. A one-way analysis of variance for correlated samples was conducted to evaluate the significance of mean changes in study endpoints. A subsequent Tukey HSD analysis was used to determine significant changes in study endpoints at each time point.

**Ethics**

All subjects provided written informed consent prior to participating in any study-related activities. The protocol and related material used in this study was approved by a commercial investigational review board (Western Institutional Review Board®, Puyallup, WA) and conformed to the good Clinical Practice guidelines of the International Conference on Harmonization. ClinicalTrials.gov Identifier NCT03066336.

**Results**

Enrolled subjects were female (n=14, 70%) and male (n=6, 30%) with a mean (SD) age of 59.9 (8.9) years. All subjects (100%) were Caucasian. Three subjects were taking systemic medications for hypertension, diabetes, and hypothyroidism. Affected great toenails were located on the right (n=11, 55%) and left foot (n=9, 45%). Two subjects recorded taking prior treatment approaches to manage their onychomycosis, which included one subject applying tree oil for a duration of 3 months and another subject applying nail lacquer for an unknown duration. Using a 1 to 5 scale to perceive effectiveness, with 1= not at all effective and 5= very effective, both subjects perceived their prior treatment approaches as “not at all effective”. The mean duration of toenail onychomycosis was 24.4 (20.2) months (range, 4 to 60 months; n=19). One outlier of 120 months was excluded. At the baseline evaluation, mean clear nail measurement of the study great toenail was 6.7 (1.8) mm and the overall mean area of clinical onychomycosis involvement of the great toenail was 40.9 (11.1) %.

A Clinical Cure was achieved for 14 (70%) of the treated great toenails while a Mycological Cure was attained for 19 (95%) great toenails. A Complete Cure was attained for 14 (70%) of the study treated great toenails. Among the 14 subjects who attained Clinical Cure, all (100%) also demonstrated Mycological Cure. Therefore, the Overall Study Success criteria was met, and overall study success was demonstrated.

The 12–month secondary endpoint of Clinical Efficacy was met by 18 (90%) toenails, Mycological Cure Rate was attained by 19 (95%) toenails and unaffected New Nail Growth, was attained by 20 (100%) toenails (p<0.0001). The mean 12–month Clinical Cure rate was 70% and the Mycological Cure rate was 95% (Table 1). Improvements were apparent beginning 3 months following the initial treatment phase and persisted throughout the study.

The mean (SD) extent of clinical onychomycosis involvement decreased from 40.9 (11.1) % at baseline to 2.6 (7.0) % at 12 months (p<0.0001) (Table 2). The mean measure of clear nail increased from 6.7 (1.8) mm at baseline to 7.9 (1.9) at the end of treatment and 13.9 (2.3) mm at 12 months (Table 3). This decrease in nail involvement was significant at 3 months (p<0.005) and each subsequent time point (p<0.0001). The number of treated nails with negative mycology cultures increased from five (25%) at the end of treatment to 19 (95%) at 12 months (Table 4).

**Discussion**

A previous retrospective study assessed the results of three nonrandomized, open-label studies using the same 635...
nm/405 nm dual-diode device to treat onychomycosis of the great toenail [26]. In that report, affected toenails (N=100) were treated for 12 minutes weekly for 2 or 4 weeks and assessed after 6 months. Most treated toenails (67%) achieved treatment success defined as achieving ≥3mm of clear nail growth and the extent of clear nail at baseline increased by a mean of 5.18 (4.76) mm after 6 months (p<0.0001). There were no adverse events.

In the current study, subjects were treated more aggressively with four weekly 12-minute treatment sessions followed by five subsequent bi-monthly treatments. The 12-month Clinical Cure rate was 70% and the Mycological Cure rate was 95%. The results compare favorably with the mycological/complete cure rate of the topical antifungal agent’s tavaborole (30–36%/6–10%) [27] and efinaconazole (53.4–55.2%/15.2–17.8%) [28] which require daily application for 48 weeks, and mycological/clinical cure rates of the oral antifungal agent’s terbinafine (78%/50%), and itraconazole (46%/30%) [29] (Table 5). Disadvantages of systemic antifungals is drug toxicity. The use of systemic antifungal, itraconazole, has reported adverse effects in 2–39% of patients, with the most common being gastrointestinal disturbances such as mild diarrhea, nausea, abdominal pain, and vomiting [30]. Furthermore, it is essential for healthcare professionals to consider drug to drug interactions when prescribing itraconazole, as many other drugs are metabolized by the same cytochrome (P450 3A4) enzyme in the liver.

Currently, a 12-week course of oral terbinafine is considered the gold standard for the treatment of onychomycosis [25]. However, the complete cure rate at 36 weeks after the completion of terbinafine in the original approval study was reported to be only 38%. Results from this clinical trial demonstrated the Lunula Laser produced a greater mycological and complete cure rate than previously FDA approved topical and systemic drugs Figures 1–3.

**Conclusion**

This study confirms the safety and effectiveness of a non-thermal 635 nm/405 nm dual-diode laser device for the treatment of onychomycosis–infected toenails following four weekly and five bi–monthly treatment sessions. This article presents data from the first completed test site of an ongoing multi-site clinical trial, further data is warranted.

**Acknowledgment**

All authors contributed equally to writing the manuscript. The authors acknowledge the editorial assistance of Dr. Carl S. Hornfeldt, Apothenon, Inc., during the preparation of this manuscript. The study was sponsored by Erchonia Corporation, Melbourne, FL. As the study sponsor, Erchonia

---

**Table 1: Clinical and Mycological Cure Rates.**

<table>
<thead>
<tr>
<th>End of Treatment Months after Treatment, n (%)</th>
<th>3</th>
<th>5</th>
<th>7</th>
<th>9</th>
<th>11</th>
<th>12</th>
<th>14</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Cure</td>
<td>0 (0)</td>
<td>2 (10)</td>
<td>5 (25)</td>
<td>3 (15)</td>
<td>3 (15)</td>
<td>7 (35)</td>
<td>14 (70)</td>
</tr>
<tr>
<td>Mycological Cure</td>
<td>5 (25)</td>
<td>12 (60)</td>
<td>15 (75)</td>
<td>20 (100)</td>
<td>17 (85)</td>
<td>19 (95)</td>
<td>19 (95)</td>
</tr>
</tbody>
</table>

**Table 2: Clinical Onychomycosis Involvement.**

<table>
<thead>
<tr>
<th>Baseline</th>
<th>End of Treatment</th>
<th>Months after Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean Percent (SD)</td>
<td>40.9 (11.1)</td>
<td>33.9 (11.5)</td>
</tr>
</tbody>
</table>

The decrease in baseline involvement was significant at each time point (p<0.0001). (Tukey’s HSD test).

**Table 3: Clear Nail Measurement.**

<table>
<thead>
<tr>
<th>Baseline</th>
<th>End of Treatment</th>
<th>Months after Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean, mm (SD)</td>
<td>6.7 (1.8)</td>
<td>7.9 (1.9)</td>
</tr>
</tbody>
</table>

The decrease in baseline involvement was significant at 3 months (p<0.005) each subsequent time point (p<0.0001) (Tukey’s HSD test).

**Table 4: Percent Negative Mycology Cultures Across Study Evaluation.**

<table>
<thead>
<tr>
<th>End of Treatment</th>
<th>Negative Mycology Culture, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>5 (25)</td>
</tr>
</tbody>
</table>

**Table 5: Comparison of Complete Cure and Mycologic Cure.**

<table>
<thead>
<tr>
<th>Laser Pharmacology™</th>
<th>Topical Antifungals</th>
<th>Oral Antifungals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Present Study</td>
<td>Efinaconazole&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Tavaborole&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Complete Cure (%)</td>
<td>70</td>
<td>15.2-17.8</td>
</tr>
<tr>
<td>Mycologic Cure (%)</td>
<td>95</td>
<td>53.4-55.2</td>
</tr>
</tbody>
</table>
was responsible for device setup and training. The study was performed at an independent physician site, which completed CITI training (Collaborative Institutional Training Initiative) and was approved through the Western Institutional Review Board (study reference # #20171235). Dr. Kerry Zang has no competing interests and was not provided any compensation for his participation in the clinical trial. Travis Sammons and Steve Shanks are employees of Erchonia Corporation (Study Sponsor). Statistical analysis of the clinical data was performed by Regulatory Insight, Inc. Elvira Walls, MS, who was the independent statistician for this clinical investigation.

References


10. Jublia® (efinaconazole) topical solution for topical use [Prescribing Information. Bausch Health US, LLC, Bridgewater, NJ.}


